HPBT
CRSP icon

Hickory Point Bank & Trust’s CRISPR Therapeutics CRSP Stock Holding History

Hickory Point Bank & Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.3K Hold
150
– – 0.01% 380
2026
Q2 		$8.18K Hold
150
– – 0.01% 365
2026
Q1 		$7.14K Buy
+150
New +$7.91K ﹤0.01% 375

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Hickory Point Bank & Trust's CRSP Position: Q3 2026 in Review

Hickory Point Bank & Trust held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 150 shares worth $8.3K. The position accounts for 0.01% of the portfolio, ranked #380.

Hickory Point Bank & Trust first reported a position in CRSP in Q1 2026 and has held it in 3 quarters since. 13 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Hickory Point Bank & Trust held 150 shares of CRISPR Therapeutics worth $8.3K as of Q3 2026.
  • Hickory Point Bank & Trust left its CRISPR Therapeutics share count unchanged in Q3 2026.
  • CRISPR Therapeutics made up 0.01% of Hickory Point Bank & Trust's portfolio in Q3 2026, its #380 holding.
  • Hickory Point Bank & Trust first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 13 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Hickory Point Bank & Trust's 13F filing for Q3 2026, filed 1 Oct 2026.